Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Pink who wrote (3412)	12/25/1997 1:58:00 AM
From: billkirn	Read Replies (1) \| Respond to of 6136

Mr. Pink: Is not irrational to reduce expectations when you are no longer funded (80%) for the development of your cancer drug hopefulls. At this time AGPH is on its own. This considerably increases the risk, and it also increases the payoff if successful. I think the market liked the comfort of Rouche taking most of the development risk and AGPH getting a good return for its 20%. I would like to see AGPH find a partner for these next two drugs AG3340 AG2043 while it develops the next generation of protease inhibitors for the Rinovirus etc. If this happens in the next few months, and as the market expands for Viracept, I think the stock will exceed its old highs. If this does not happen, my guess is it will move more slowly toward 60 over the next 12 months. What a great group on this thread. Merry Christmas to all and may the new year bring you happiness and satisfaction first, and financial success second. Bill